FDA Advocacy

The National Women’s Health Network’s 2024 Policy Agenda

By NWHN Staff | Jan 24, 2024 | Comments Off on The National Women’s Health Network’s 2024 Policy Agenda

The NWHN Urges the Supreme Court to Validate the Safety of Mifepristone as it Prepares to Hear Oral Arguments in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration 

By NWHN Staff | Dec 13, 2023 | Comments Off on The NWHN Urges the Supreme Court to Validate the Safety of Mifepristone as it Prepares to Hear Oral Arguments in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration 

The 5th Circuit Court of Appeals ignored 23 years of scientific evidence when it restricted access to Mifepristone.

Ensuring Accessible Birth Control: Opill and the Path Forward

By Kristen Batstone | Jul 24, 2023 | Comments Off on Ensuring Accessible Birth Control: Opill and the Path Forward

The NWHN Applauds the FDA’s Decision to Make a Birth Control Pill Available Over-the-Counter

By Carter Ringo | Jul 13, 2023 | Comments Off on The NWHN Applauds the FDA’s Decision to Make a Birth Control Pill Available Over-the-Counter

OPill is the first over-the-counter birth control pill available in the U.S. It is safe, effective, and will increase access to contraception for millions of women nationwide.

020: How the FDA Works and How Advocates Work With It with Kirsten Moore

By Carter Ringo | Jun 1, 2023 | Comments Off on 020: How the FDA Works and How Advocates Work With It with Kirsten Moore

The NWHN’s Statement on the FDA Lifting Unnecessary Restrictions on Medication Abortion

By NWHN Staff | Apr 13, 2021 | Comments Off on The NWHN’s Statement on the FDA Lifting Unnecessary Restrictions on Medication Abortion

Late last night, the FDA announced that, effective immediately, both medication abortion and miscarriage patients would be able to access mifepristone via delivery from their providers or through mail-order pharmacies. This tremendous victory will ensure that patients and providers are protected during the pandemic.

FDA Meeting – Emergency Use Authorization of the Johnson & Johnson/Janssen Biotech Inc. COVID-19 Vaccine

By Sarah Christopherson | Feb 26, 2021 | Comments Off on FDA Meeting – Emergency Use Authorization of the Johnson & Johnson/Janssen Biotech Inc. COVID-19 Vaccine

Testimony Delivered to the Vaccines and Related Biological Products Advisory Committee

Your Questions About the New COVID-19 Vaccines – Answered

By Sarah Christopherson | Dec 14, 2020 | Comments Off on Your Questions About the New COVID-19 Vaccines – Answered

How safe are the vaccines? How effective? Were they tested in people like me? Was the approval process influenced by political pressure? Here’s what we know.

FDA Meeting – Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine

By Sarah Christopherson | Dec 10, 2020 | Comments Off on FDA Meeting – Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine

Testimony Delivered to the Vaccines and Related Biological Products Advisory Committee

FDA Meeting – Development, authorization and licensure of vaccines to prevent COVID-19

By Sarah Christopherson | Oct 22, 2020 | Comments Off on FDA Meeting – Development, authorization and licensure of vaccines to prevent COVID-19

Testimony Delivered to the Vaccines and Related Biological Products Advisory Committee